Abstract Number: 1478 • ACR Convergence 2023
Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with SLE and Posterior reversible encephalopathy syndrome (PRES). Methods: We performed a multicenter cohort…Abstract Number: 1600 • ACR Convergence 2023
Transcriptomic Characterization of Class II Lupus Nephritis and Outcomes
Background/Purpose: Lupus Nephritis (LN) significantly reduces the survival and life expectancy of patients with SLE. Given this, considerable effort has gone into characterizing the histologic…Abstract Number: 2315 • ACR Convergence 2023
Assessing Lupus Disease Activity Following the Onset of End-Stage Kidney Disease Within a Single Tertiary Centre in South London
Background/Purpose: Lupus nephritis represents a severe manifestation of SLE and is associated with a risk of progression to end-stage kidney disease (ESKD) if untreated, leading…Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…Abstract Number: 0915 • ACR Convergence 2023
IL-16+ Is Abundantly Expressed by Kidney-infiltrating Myeloid and Lymphoid Cells in Lupus Nephritis: A Spatially Resolved Multiplexed Approach
Background/Purpose: We previously discovered that IL-16 is the urinary protein most strongly correlated with histological activity in lupus nephritis (LN), followed by neutrophil degranulation products…Abstract Number: 1480 • ACR Convergence 2023
Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region
Background/Purpose: Data from limited studies of LN in the Gulf region suggest that LN manifests more severely in this region than in Caucasian populations, yet…Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…Abstract Number: 2326 • ACR Convergence 2023
Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis and is a mediator of progressive kidney damage. Early reductions in urine protein creatinine ratio…Abstract Number: 0740 • ACR Convergence 2023
Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease
Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators…Abstract Number: 0920 • ACR Convergence 2023
Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB
Background/Purpose: Ultraviolet B (UVB) exposure triggers lupus flare by worsening both skin lesions and systemic symptoms, i.e. lupus nephritis. We recently reported that UVB exposure…Abstract Number: 1481 • ACR Convergence 2023
Racial Disparities in Lupus Nephritis: A Nationwide Analysis
Background/Purpose: Lupus nephritis (LN) is a significant predictor of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Racial disparities are known to exist in SLE…Abstract Number: 1652 • ACR Convergence 2023
Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders
Background/Purpose: Black/African American people with lupus (PWL) experience greater disease prevalence and severity than White PWL. The need for more racial and ethnic diversity amongst…Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…Abstract Number: 0781 • ACR Convergence 2023
Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials
Background/Purpose: Traditional induction treatment regimens for proliferative or membranous lupus nephritis (LN) have utilized oral glucocorticoids (GC) in initial doses up to 1.0 mg/kg/day prednisone…Abstract Number: 0921 • ACR Convergence 2023
SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis
Background/Purpose: Better understanding of the abnormal immune responses in lupus nephritis (LN) is fundamental to identifying new therapies. We previously reported that the adaptor protein…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 37
- Next Page »